- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings
In light of 2 blockbuster originators, namely Humira (adalimumab) and Stelara (ustekinumab), losing market exclusivity in 2023, 3 doctors penned supplement in The American Journal of Managed Care®. On this episode, Vibeke Strand, MD, one of the co-authors, explored how health systems can take charge and boost biosimilar adoption.
It's no secret that the immunology space for biosimilars is growing and growing fast, with between 8 and 10 adalimumab biosimilars and at least 2 ustekinumab biosimilars expected to launch in the United States throughout 2023. In light of 2 of the most profitable originators, namely Humira (adalimumab) and Stelara (ustekinumab), losing market exclusivity around the same time, 3 doctors in the immunology space penned a 3-article supplement in The American Journal of Managed Care® entitled "Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update."
The Center for Biosimilars®, the sister website of The American Journal of Managed Care®, is conducting a multimedia interview series with the authors to expand on some of the information presented in the supplement. On this episode of Not So Different, we spoke with Vibeke Strand, MD, one of the co-authors and an adjunct clinical professor in the Division of Immunology/Rheumatology at Stanford University School of Medicine. We discussed the article "Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence" as well as how health systems can take charge and try to boost biosimilar adoption.
Show notes
To read all the articles within the supplement, click here.
To read the article references in this episode, click here.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.
